A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas.

Trial Profile

A Phase IB/II Study of Escalating Doses of Romidepsin (Istodax) in Association With CHOP (Ro-CHOP) in the Treatment of Peripheral T-Cell Lymphomas.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Romidepsin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Dec 2014 Results published in Celgene media release.
    • 09 Dec 2014 Based on phase I results (n=18), the recommended dose of romidepsin for the phase II portion was 12 mg/m2, according to a Celgene Corporation media release.
    • 09 Dec 2014 Results were presented at the 56th American Society of Hematology annual meeting, according to a Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top